Technical Analysis for CRBP - Corbus Pharmaceuticals Holdings, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 16.57 | 2.28% | 0.37 |
CRBP closed up 2.28 percent on Wednesday, October 30, 2024, on 34 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bearish | Bearish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 2.28% | |
| Doji - Bullish? | Reversal | 2.28% | |
| Oversold Stochastic | Weakness | 2.28% | |
| NR7 | Range Contraction | 1.41% | |
| Narrow Range Bar | Range Contraction | 1.41% | |
| Lower Bollinger Band Walk | Weakness | 1.41% | |
| Inside Day | Range Contraction | 1.41% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 16 hours ago |
| Up 5% | about 16 hours ago |
| Up 3% | about 17 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| Outside Day | about 17 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel therapeutics to treat inflammatory-fibrotic diseases. The company primarily develops Resunab, an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and diffuse scleroderma. It sells its products through hearing professionals, including audiologists, hearing aid specialists, and ENT doctors worldwide. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Hearing Cystic Fibrosis Hearing Aid Fibrotic Disease Treatment Of Cystic Fibrosis Ajulemic Acid Channelopathies Scleroderma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Hearing Cystic Fibrosis Hearing Aid Fibrotic Disease Treatment Of Cystic Fibrosis Ajulemic Acid Channelopathies Scleroderma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 61.9 |
| 52 Week Low | 3.0334 |
| Average Volume | 737,591 |
| 200-Day Moving Average | 38.84 |
| 50-Day Moving Average | 34.05 |
| 20-Day Moving Average | 18.04 |
| 10-Day Moving Average | 17.08 |
| Average True Range | 1.74 |
| RSI (14) | 27.01 |
| ADX | 49.5 |
| +DI | 11.78 |
| -DI | 36.82 |
| Chandelier Exit (Long, 3 ATRs) | 15.66 |
| Chandelier Exit (Short, 3 ATRs) | 21.15 |
| Upper Bollinger Bands | 20.40 |
| Lower Bollinger Band | 15.68 |
| Percent B (%b) | 0.19 |
| BandWidth | 26.16 |
| MACD Line | -4.29 |
| MACD Signal Line | -5.25 |
| MACD Histogram | 0.9561 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.36 | ||||
| Resistance 3 (R3) | 18.35 | 17.74 | 18.07 | ||
| Resistance 2 (R2) | 17.74 | 17.28 | 17.75 | 17.97 | |
| Resistance 1 (R1) | 17.15 | 17.00 | 17.45 | 17.17 | 17.87 |
| Pivot Point | 16.54 | 16.54 | 16.69 | 16.55 | 16.54 |
| Support 1 (S1) | 15.96 | 16.09 | 16.25 | 15.97 | 15.27 |
| Support 2 (S2) | 15.35 | 15.80 | 15.35 | 15.17 | |
| Support 3 (S3) | 14.76 | 15.35 | 15.07 | ||
| Support 4 (S4) | 14.78 |
